文献速递治疗药物监测与药物基因组学药物相互作用

基于药物代谢组学与遗传信息预测华法林初始剂量范围

Predicting Range of Initial Warfarin Dose Based on Pharmacometabolomic and Genetic Inputs.
PubMed 文献 · Clin Pharmacol Ther · 2021-09-13

本研究纳入160例心脏瓣膜病患者,结合基线代谢轮廓、基因型及临床信息,构建模型预测出院前末次INR(INRday7)。偏最小二乘模型显示两个基线代谢物(尿苷和鸟苷)、VKORC1单核苷酸变异及四个临床参数对INRday7有良好预测力。基于此开发的IniWarD算法可预测初始7天华法林有效剂量范围,较传统基因型方法更合适,或可避免出血或血栓风险。

要点

  • 基线尿苷、鸟苷、VKORC1变异及体重、肌酐、胺碘酮使用和初始剂量可预测INRday7。
  • 机器学习算法预测华法林敏感亚组的准确率训练集91%、测试集90%。
  • IniWarD系统建议的初始7天日剂量范围优于传统基因型方法。

核心结论

  • 结合药物代谢组学与药物遗传学数据可有效预测华法林初始治疗反应,IniWarD算法建议的日剂量范围较传统基因型方法更合适。

研究设计与样本

  • 研究纳入160例心脏瓣膜病患者,以基线代谢轮廓、基因型和临床信息为变量,构建预测出院前末次INR(INRday7)的模型。

主要发现

  • 偏最小二乘模型显示两个基线代谢物(尿苷和鸟苷)、一个单核苷酸变异(VKORC1)和四个临床参数(体重、肌酐水平、胺碘酮使用和初始日剂量)对INRday7有良好预测力(训练集R²=0.753,测试集R²=0.643)。
  • 机器学习算法(二维线性判别分析-多项logit模型)预测华法林极敏感或不敏感亚组的准确率训练集为91%,测试集为90%。

关键数值与推荐

  • IniWarD系统基于上述生物标志物设计,用于预测初始7天华法林治疗的有效剂量范围。

临床怎么用

  • 临床可基于基线代谢物(尿苷、鸟苷)、VKORC1基因型及体重、肌酐、胺碘酮使用等参数,使用IniWarD算法辅助制定华法林初始日剂量范围。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Anticoagulation response to warfarin during the initial stage of therapy varies among individuals. In this study, we aimed to combine pharmacometabolomic and pharmacogenetic data to predict interindividual variation in warfarin response, and, on this basis, suggest an initial daily dose range. The baseline metabolic profiles, genotypes, and clinical information of 160 patients with heart valve disease served as the variables of the function of the last international normalized ratio measured before a patient's discharge (INRday7 ) to screen for potential biomarkers. The partial least-squares model showed that two baseline metabolites (uridine and guanosine), one single-nucleotide variation (VKORC1), and four clinical parameters (weight, creatinine level, amiodarone usage, and initial daily dose) had good predictive power for INRday7 (R2 = 0.753 for the training set, 0.643 for the test set). With these biomarkers, a machine learning algorithm (two-dimensional linear discriminant analysis-multinomial logit model) was used to predict the subgroups with extremely warfarin-sensitive or less warfarin-sensitive patients with a prediction accuracy of 91% for the training set and 90% for the test set, indicating that individual responses to warfarin could be effectively predicted. Based on this model, we have successfully designed an algorithm,"IniWarD," for predicting an effective dose range in the initial 7-day warfarin therapy. The results indicate that the daily dose range suggested by the IniWarD system is more appropriate than that of the conventional genotype-based method, and the risk of bleeding or thrombus due to warfarin could thus be avoided.

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Huang Q, Cao L, Luo N, et al. Predicting Range of Initial Warfarin Dose Based on Pharmacometabolomic and Genetic Inputs. Clin Pharmacol Ther. 2021. PMID: 34460938. doi:10.1002/cpt.2407

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。